Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 15/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ESRRA | P11474 | 1/20 | 0.44 |
| ▸ | PTPRF | P10586 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6566675 | 0.89 | CASR (0.57) | CASRMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6566680 | 0.88 | CASR (0.56) | CASRMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6565789 | 0.88 | CASR (0.56) | CASRMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6567665 | 0.88 | CASR (0.56) | CASRMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6566863 | 0.88 | CASR (0.55) | CASRMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6566611 | 0.87 | CASR (0.54) | CASRMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6566826 | 0.86 | GAA (0.54) | CASRMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6567780 | 0.86 | CASR (0.53) | CASRMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6564673 | 0.86 | CASR (0.53) | CASRMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6564786 | 0.85 | KMT2A (0.61) | CASRMEN1LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | CASR 1621/4885MEN1 4143/4885LMNA 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.